AMDOXOVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H12N6O3
Molecular Weight	252.23
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC2=C(N=CN2[C@H]3CO[C@@H](CO)O3)C(N)=N1

InChI

InChIKey=RLAHNGKRJJEIJL-RFZPGFLSSA-N

InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C9H12N6O3
Molecular Weight	252.23
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15351346
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800004771

Amdoxovir is a guanosine analogue nucleoside reverse transcriptase inhibitor that is active in vitro against both HIV-1 and HBV. It is deaminated intracellularly by adenosine deaminase to dioxolane guanine (DXG). DXG-triphosphate, the active form of the drug, has greater activity than DAPD-triphosphate. Amdoxovir is under development (phase II study) for the treatment of HIV infection. Five subjects demonstrated lens opacities during the study, although baseline evaluations were not performed. Clinical studies of amdoxovir are currently on hold pending additional safety data.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
DNA polymerase/reverse transcriptase 10 Target ID: CHEMBL2362994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10760047	Inhibitor 8504	0.61 µM [IC50]
Adenosine deaminase 14 Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11120959	Substrate 661
Human immunodeficiency virus type 1 reverse transcriptase 70 Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11120959 \| http://adisinsight.springer.com/drugs/800004771	Inhibitor 8504	0.019 µM [Ki]
DNA polymerase beta 5 Target ID: CHEMBL2392 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11120959	Inhibitor 8504	32.0 µM [Ki]
DNA polymerase alpha subunit 9 Target ID: CHEMBL1828 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11120959	Inhibitor 8504	78.0 µM [Ki]
DNA polymerase gamma subunit 1 2 Target ID: CHEMBL2732 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11120959	Inhibitor 8504	4.3 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16964830	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1545 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/20038617	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		1,3-DIOXOLANE GUANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
499 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20038617	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMDOXOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
6834 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/20038617	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		1,3-DIOXOLANE GUANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1326 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20038617	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMDOXOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
17.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/20038617	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		1,3-DIOXOLANE GUANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20038617	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMDOXOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16184030	unhealthy Health Status: unhealthy Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/16184030	Sources: https://pubmed.ncbi.nlm.nih.gov/16184030

Sourcing

Vendor/Aggregator	ID	URL
BOC Sciences	145514-04-1	http://www.bocsci.com/description.asp?cas=145514-04-1
Compound Cloud	124088
eMolecules	109867526	https://orderbb.emolecules.com/search/#?query=109867526
eMolecules	76746369	https://orderbb.emolecules.com/search/#?query=76746369
MuseChem	M091480	https://www.musechem.com/product/M091480.html

PubMed

Title	Date	PubMed
1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes.	1993 Jan 8	8421287
Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.	1999 Apr-May	10432704
Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus.	2000 Nov	11114413
Highlights in the development of new antiviral agents.	2002 Apr	12370077
In vitro activity of potential anti-poxvirus agents.	2003 Jan	12615301
New antiretroviral drugs.	2003 Mar	12667250
Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.	2003 May 23	12651859
HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.	2004 Sep	15183346
New targets and new drugs in the treatment of HIV.	2005 Jul	16373002
Gateways to clinical trials.	2005 Jun	16082422
Emerging anti-HIV drugs.	2005 May	15934866
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.	2005 Oct 14	16184030
New trends in nucleoside biotechnology.	2010 Jul	22649640

Patents

Sample Use Guides

In Vivo Use Guide

300 mg twice daily

Route of Administration: Oral

In Vitro Use Guide

Amdoxovir proved equipotent at inhibiting HBV replication in HepG2 2.2.15, HepAD79 and HepAD38 cells with EC50 13, 16 and 14 ug/ml respectively.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:59:51 GMT 2025` Edited by `admin` on `Wed Apr 02 09:59:51 GMT 2025`
Record UNII	54I81H0M9C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMDOXOVIR

Official Name

English

DAPD

Preferred Name

English

Amdoxovir [WHO-DD]

Common Name

English

(-)-DAPD

Common Name

English

amdoxovir [INN]

Common Name

English

AMDOXOVIR [USAN]

Common Name

English

1,3-DIOXOLANE-2-METHANOL, 4-(2,6-DIAMINO-9H-PURIN-9-YL)-, (2R,4R)-

Systematic Name

English

(2R,4R)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97452